Abstract:Background Proton pump inhibitors (PPIs) are usually prescribed to patients undergoing dual antiplatelet therapy to decrease the risk of gastrointestinal bleeding. However, the proportion of patients increased incidence of major adverse cardiovascular event because of interaction of PPIs and clopidogrel. The aim of the study was to assess the effect of omeprazole and pantoprazole on platelet reactivity in acute coronary syndrome patients receiving clopidogrel. Method From October 2012 to September 2013, a total of 620 consecutive acute coronary syndrome patients from Shenyang General Hospital were enrolled. All patients received clopidogrel loading dose 300 mg and aspirin 300 mg. Patients were randomised to two groups by the ratio of 1:1 and received routine dual anti-platelet treatment. The omeprazole group (aspirin 300 mg/d and clopidogrel 75 mg/d and omeprazole 20 mg/d, n = 310). The pantoprazole group (aspirin 300 mg/d and clopidogrel 75 mg/d and pantoprazole 20 mg/d, n = 310). The reversion rate of ADP which was defined as 20 μmol/L adenosine diphosphate induced platelet aggregation (by LTA) (on admission, three days and 30 days after dual antiplatelet therapy) and clinical events (stent thrombosis, MACEs, which included cardiac death, myocardial infarction or ischaemic symptoms driven target vessel revascularisation, all-cause death, TIMI) were observed. Result All groups were generally well balanced with regard to baseline demographic, clinical, and proced-ural characteristics. There were no different on platelet response to clopidogrel at three days (52.8% ± 19.3% vs 50.2% ± 19.3%, respectively, p = 0.384) and 30 days (49.9% ± 14.9% vs 49.1% ± 14.7%, respectively, p = 0.559) between omeprazole group and pantoprazole group. 1 stent thrombosis in the omeprazole group and 0 stent thrombosis in pantoprazole group (p = 0.219). 2 patients in omeprazole group were suffered from MACE (0.6%), and 3 patients in pantoprazole group (0.97%, p = 0.359). In addition, there were no major or minor bleeding in the two groups, the minimal bleeding in omeprazole and pantoprazole groups were no significantly difference (2.1% vs 2.8%, respectively, p = 0.235). There was no significantly association between the two groups for all-cause death (p = 0.687), and 1 patient died due to the traumatic brain injury in the omeprazole group. Conclusion These results suggest that the drug interaction between PPIs (omeprazole and pantoprazole)and clopidogrel does not result in ADP induced platelet aggregation. There was no apparent clinical events interaction between clopidogrel and omeprazole and pantoprazole in patients who received dual antiplatelet therapy. The clinic impact of this strategy needs to be proved by long term follow-up outcome studies.

Effects of Rabeprazole on Pharmacokinetics of Clopidogrel in Rats

Drug–drug Interaction of Rabeprazole and Clopidogrel in Healthy Chinese Volunteers

The Effect of Clopidogrel on Pharmacokinetics of Ivabradine and Its Metabolite in Rats

[Effects of Proton Pump Inhibitors on In-Stent Restenosis in Patients Receiving Clopidogrel: a Retrospective Analysis].

Effects of Extract of Schisandra chinensis Baill on Clopidogrel Pharmacokinetic for Rats

Effects of Ticagrelor on the Pharmacokinetics of Rivaroxaban in Rats.

Decreased Plasma Exposure of Clopidogrel Active Metabolite in Rats after Long‐term Treatment with Clopidogrel

Pharmacokinetic characteristics of clopidogrel in rats after single dose and multiple doses of oral administration

The Safety of Long-term Combined Application of Rabeprazole and Clopidogrel in the Elderly

Safety of Rebeprazole in Acute Coronary Syndrome Patients with Dual Anti-platelet Therapy after Percutaneous Coronary Intervention

Pharmacodynamic Effects and Kinetic Disposition of Rabeprazole in Relation to CYP2C19 Genotype in Healthy Chinese Subjects1

The Effects of Rabeprazole on Metformin Pharmacokinetics and Pharmacodynamics in Chinese Healthy Volunteers

Effect of scutellarin on the metabolism and pharmacokinetics of clopidogrel in rats.

The Drug Interactions Study of Clopidogrel in vitro

Effect of Clopidogrel on Aspirin Resistance in Acute Coronary Syndrome Patients

ASSA14-03-35 Effects of Omeprazole and Pantoprazole on Platelet Function in Acute Coronary Syndrome Patients Receiving Clopidogrel: A Single-centre Prospective Randomised Controlled Clinical Trials

Mechanistic Understanding of the Effect of Dengzhan Shengmai Capsule on the Pharmacokinetics of Clopidogrel in Rats.

Impact of pantoprazole on clopidogrel's anti-platelet effect in patients with acute coronary syndrome

Combined Pharmacokinetics-pharmacodynamics Study of Rabeprazole in Inhibition of Gastric Acid Secretion

A Meta‐Analysis of Impact of Proton Pump Inhibitors on Antiplatelet Effect of Clopidogrel

Effects of Omeprazole on Pharmacokinetics of Oxiracetam in Rats